✦ LIBER ✦

Liposomal daunorubicin (DaunoXome) for treatment of poor-risk acute leukemia

✍ Scribed by D. Russo; P. Piccaluga; M. Michieli; T. Michelutti; G. Visani; L. Gugliotta; A. Bonini; I. Pierri; M. Gobbi; M. Tiribelli; R. Fanin; S. Piccolrovazzi; M. Baccarani

Publisher: Springer
Year: 2002
Tongue: English
Weight: 37 KB
Volume: 81
Category: Article
ISSN: 0939-5555
DOI: 10.1007/s00277-002-0509-9

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Combination of liposomal daunorubicin (D

Combination of liposomal daunorubicin (DaunoXome), fludarabine, and cytarabine (FLAD) in patients with poor-risk acute leukemia

✍ Marino Clavio; Claudia Venturino; Ivana Pierri; Alberto Garrone; Maurizio Miglin 📂 Article 📅 2004 🏛 Springer 🌐 English ⚖ 113 KB

Sequential continuous infusion of fludar

Sequential continuous infusion of fludarabine and cytarabine associated with liposomal daunorubicin (DaunoXome®) (FLAD) in primary refractory or relapsed adult acute myeloid leukemia patients

✍ Andrea Camera; Ciro R. Rinaldi; Salvatore Palmieri; Nicola Cantore; Giuseppina M 📂 Article 📅 2008 🏛 Springer 🌐 English ⚖ 159 KB

A randomized trial of liposomal daunorub

A randomized trial of liposomal daunorubicin and cytarabine versus liposomal daunorubicin and topotecan with or without thalidomide as initial therapy for patients with poor prognosis acute myelogenous leukemia or myelodysplastic syndrome

✍ Jorge Cortes; Hagop Kantarjian; Maher Albitar; Deborah Thomas; Stefan Faderl; Ch 📂 Article 📅 2003 🏛 John Wiley and Sons 🌐 English ⚖ 102 KB

## Abstract ## BACKGROUND Because angiogenesis may play a role in the pathogenesis of acute myeloid leukemia (AML) and high‐risk myelodysplastic syndrome (MDS), and thalidomide (Th) has shown significant anti‐angiogenic activity, this study was designed to investigate the potential role of Th in t

Fludarabine, cytarabine, and G-CSF (FLAG

Fludarabine, cytarabine, and G-CSF (FLAG) for the treatment of poor risk acute myeloid leukemia

✍ Montillo, Marco; Mirto, Salvatore; Petti, Maria Concetta; Latagliata, Roberto; M 📂 Article 📅 1998 🏛 John Wiley and Sons 🌐 English ⚖ 45 KB 👁 2 views

Thirty-eight patients with primary resistant or relapsing acute myeloid leukemia (AML) were treated with fludarabine, cytarabine and granulocyte colony-stimulating factor (FLAG). Median age was 41 (range 11-70). Sixteen patients had AML that was primary resistant to induction treatment, while 22 wer

Treatment of “poor risk” acute nonlympho

Treatment of “poor risk” acute nonlymphocytic leukemia with continuously infused low-dose cytosine arabinoside

✍ Dr. Edward P. Balaban; John V. Cox; Nancy R. Schneider; Cheryl A. Harth; Barbara 📂 Article 📅 1988 🏛 John Wiley and Sons 🌐 English ⚖ 431 KB 👁 2 views

All-transretinoic acid plus low doses of

All-transretinoic acid plus low doses of cytarabine for the treatment of “poor-risk” acute myeloid leukemias

✍ A. Venditti; R. Stasi; M. Masi; G. Del Poeta; C. Cox; A. Franchi; D. Piccioni; A 📂 Article 📅 1993 🏛 Springer 🌐 English ⚖ 163 KB